Purple Biotech's CM24 Shows Improved Survival in Phase 2 Data
Ticker: PPBT · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1614744
Sentiment: bullish
Topics: phase-2, clinical-data, oncology
TL;DR
Purple Biotech's CM24 drug shows improved survival in Phase 2 data at ASCO 2024.
AI Summary
Purple Biotech Ltd. announced positive interim Phase 2 data for its CM24 drug at ASCO 2024 on June 1, 2024. The data demonstrated improved overall survival in patients treated with CM24. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.
Why It Matters
Positive Phase 2 data for CM24 could advance the drug's development and potentially offer a new treatment option for patients, impacting future clinical trials and market potential.
Risk Assessment
Risk Level: medium — Phase 2 data is promising but not yet definitive, and further trials are needed to confirm efficacy and safety.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- CM24 (drug) — Drug candidate
- ASCO 2024 (event) — Conference where data was presented
- June 1, 2024 (date) — Date of press release
- Kitov Pharma Ltd. (company) — Former company name
FAQ
What specific improvements in overall survival were observed with CM24?
The filing states that the data demonstrated improved overall survival, but specific quantitative improvements are not detailed in this excerpt.
What is the current stage of development for CM24?
The data presented is from a randomized Phase 2 trial.
When was the press release announcing these results issued?
The press release was issued on June 1, 2024.
What is Purple Biotech Ltd.'s former name?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd.
Where is Purple Biotech Ltd. headquartered?
Purple Biotech Ltd. is headquartered in Rehovot, Israel.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-06-03 06:21:37
Filing Documents
- ea0207189-6k_purple.htm (6-K) — 14KB
- ea020718902ex99-1_purple.htm (EX-99.1) — 29KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-048752.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. June 3, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2